Clinical Trial Update: Zalutumumab in Patients With Non-curable Head and Neck Cancer [Phase 3]

View source ↗

Summary

This Phase 3 trial evaluated Zalutumumab in patients with non-curable head and neck squamous cell carcinoma; results were posted in 2013.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Head and Neck Squamous Cell Carcinoma

Drugs mentioned

• Zalutumumab (zalutumumab)

Snippet

Sponsor: Genmab | Conditions: Head and Neck Cancer, Squamous Cell Cancer | Phase 3 | Status: COMPLETED | Results posted: 2013-10-15